These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30748023)

  • 1. Utilization of Adult Data in Designing Pediatric Pharmacokinetic Studies: How Much Are Historical Adult Data Worth?
    Hsu CH; Steven Xu X; Wang J; Zhang L; Liu C; Wang Y
    J Clin Pharmacol; 2019 Jul; 59(7):989-996. PubMed ID: 30748023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical appraisal of Bayesian dynamic borrowing from an imperfectly commensurate historical control.
    Harun N; Liu C; Kim MO
    Pharm Stat; 2020 Sep; 19(5):613-625. PubMed ID: 32185886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of historical control data for assessing treatment effects in clinical trials.
    Viele K; Berry S; Neuenschwander B; Amzal B; Chen F; Enas N; Hobbs B; Ibrahim JG; Kinnersley N; Lindborg S; Micallef S; Roychoudhury S; Thompson L
    Pharm Stat; 2014; 13(1):41-54. PubMed ID: 23913901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian hypothesis testing with frequentist characteristics in clinical trials.
    Quan H; Zhang B; Lan Y; Luo X; Chen X
    Contemp Clin Trials; 2019 Dec; 87():105858. PubMed ID: 31669448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirical profile Bayesian estimation for extrapolation of historical adult data to pediatric drug development.
    Wu Y; Hui J; Deng Q
    Pharm Stat; 2020 Nov; 19(6):787-802. PubMed ID: 32573051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal sample size determination for single-arm trials in pediatric and rare populations with Bayesian borrowing.
    Ji Z; Lin J; Lin J
    J Biopharm Stat; 2022 Jul; 32(4):529-546. PubMed ID: 35604836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A scaled kernel density estimation prior for dynamic borrowing of historical information with application to clinical trial design.
    Warren JL; Wang Q; Ciarleglio MM
    Stat Med; 2024 Apr; 43(8):1615-1626. PubMed ID: 38345148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian hierarchical model for dose-finding trial incorporating historical data.
    Han L; Deng Q; He Z; Fleischer F; Yu F
    J Biopharm Stat; 2024 Aug; 34(5):646-660. PubMed ID: 37676029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian adaptive randomization design incorporating propensity score-matched historical controls.
    Sawamoto R; Oba K; Matsuyama Y
    Pharm Stat; 2022 Sep; 21(5):1074-1089. PubMed ID: 35278032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation.
    Gamalo-Siebers M; Savic J; Basu C; Zhao X; Gopalakrishnan M; Gao A; Song G; Baygani S; Thompson L; Xia HA; Price K; Tiwari R; Carlin BP
    Pharm Stat; 2017 Jul; 16(4):232-249. PubMed ID: 28448684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
    Hupf B; Bunn V; Lin J; Dong C
    Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel power prior approach for borrowing historical control data in clinical trials.
    Shi Y; Li W; Liu GF
    Stat Methods Med Res; 2023 Mar; 32(3):493-508. PubMed ID: 36601652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
    Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
    Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Historical controls in clinical trials: a note on linking Pocock's model with the robust mixture priors.
    Callegaro A; Galwey N; Abellan JJ
    Biostatistics; 2023 Apr; 24(2):443-448. PubMed ID: 37057610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating historical two-arm data in clinical trials with binary outcome: A practical approach.
    Feißt M; Krisam J; Kieser M
    Pharm Stat; 2020 Sep; 19(5):662-678. PubMed ID: 32227680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
    Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
    BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporating historical controls in clinical trials with longitudinal outcomes using the modified power prior.
    Qi H; Rizopoulos D; Lesaffre E; van Rosmalen J
    Pharm Stat; 2022 Sep; 21(5):818-834. PubMed ID: 35128780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian borrowing from historical control data in a vaccine efficacy trial.
    Peng L; Jin J; Chambonneau L; Zhao X; Zhang J
    Pharm Stat; 2023; 22(5):815-835. PubMed ID: 37226586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints.
    Bi D; Liu M; Lin J; Liu R
    Stat Med; 2023 Dec; 42(30):5708-5722. PubMed ID: 37858287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study.
    Wang X; Suttner L; Jemielita T; Li X
    J Biopharm Stat; 2022 Jan; 32(1):170-190. PubMed ID: 34939894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.